[{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaCyte Biotech Successfully Develops \u201cChange History\u201d for its Clinical Trial Product for Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaCyte Biotech Announces Submission of Drug Master File to FDA for Company\u2019s Pancreatic Cancer Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Formally Accepts PharmaCyte Biotech\u2019s Drug Master File for Company\u2019s Pancreatic Cancer Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaCyte Biotech Announces IND Submitted to U.S. FDA for Clinical Trial in Locally Advanced, Inoperable Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaCyte Biotech\u2019s Investigational New Drug Application Placed on Hold by the U. S. FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaCyte Biotech Successfully Completes 9-Month Stability Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaCyte Biotech Begins DNA Sequence and Stability Studies in Response to FDA Requests for its Clinical Trial Product","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaCyte Biotech Provides Update on Status of Activities to Lift Clinical Hold","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"H.C. Wainwright","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"PharmaCyte Biotech Announces Uplist Date to NASDAQ and Pricing of $15 Million Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"H.C. Wainwright","pharmaFlowCategory":"D","amount":"$70.0 million","upfrontCash":"Undisclosed","newsHeadline":"PharmaCyte Biotech Announces Closing of $70 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$90.0 million","upfrontCash":"Undisclosed","newsHeadline":"PharmaCyte Biotech Expands Product Pipeline to Include Diabetes and Malignant Ascites Following $90-Million Capital Raise","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaCyte Biotech Establishes 18-Month Shelf Life for Clinical Trial Product in Ongoing Stability Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaCyte Biotech Launches Malignant Ascites Program with Commencement of Pivotal Preclinical Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaCyte Biotech Study Proves Capsule Material is Not Toxic for Encapsulated Cells","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaCyte Biotech Updates Status of Investigational New Drug Application to FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaCyte Biotech Successfully Completes 24-Month Stability Study of Its Clinical Trial Product Candidate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaCyte Biotech to Accelerate Preparations for Start of Pancreatic Cancer Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaCyte Biotech Announces More Positive Tests Results for Its Pancreatic Cancer Clinical Trial Product Candidate to Satisfy FDA Requirements","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Heidelberg Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"CBSET","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaCyte Biotech Commences First Phase of Two-Phase Pig Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"MyMD Pharmaceuticals","pharmaFlowCategory":"D","amount":"$7.0 million","upfrontCash":"Undisclosed","newsHeadline":"PharmaCyte Biotech Makes $7 Million Investment in MyMD for Inflammatory Disease","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III"}]
Find Clinical Drug Pipeline Developments & Deals by PharmaCyte Biotech
The financing aims to support MyMD in advancing its lead product MYMD-1 (isomyosamine), which is being evaluated in the mid-stage clinical trial studies for the treatment of sarcopenia.
The objective of this pilot study is to assess microcatheter-based delivery of CypCaps in the pancreatic arterial system. volume of dose, number of CypCaps, and treatment location will be evaluated using imaging and histology.
The study has achieved positive interim results in its study to establish a malignant ascites mouse model which will form the basis for further testing of the effectiveness of its CypCaps plus ifosfamide pancreatic cancer therapy for the treatment of malignant ascites.
CypCaps showed, no evidence of toxicity in this animal study in any of the parameters examined and that the study confirms previous data that the capsule material is inert.
Lead Product(s):
Encapsulated Live Cells Ifosamide Prodrug
CypCaps are genetically engineered human cells, specifically engineered to treat unresectable pancreatic cancer, and encapsulated using PharmaCyte's Cell-in-a-Box technology.
Lead Product(s):
Encapsulated Live Cells Converting Ifosamide
The significance of this timepoint is that CypCaps (encapsulated live cells converting ifosamide) has now demonstrated that it has a shelf life of at least 24 months when stored at -80 degree, also maintain viability, enzymatic activity and cell potency.
Lead Product(s):
Encapsulated Live Cells Ifosamide Prodrug
PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active (Ifosfamide) or “cancer-killing” form.
Lead Product(s):
Encapsulated Live Cells Converting Ifosamide
Study demonstrates that the CypCap capsule material is not in any way toxic to encapsulated live cells, the material is bio-inert and used to treat locally advanced, inoperable pancreatic cancer.
Lead Product(s):
Encapsulated Live Cells Converting Ifosamide
PharmaCyte uses for locally advanced, inoperable pancreatic cancer—Cell-in-a-Box (CypCaps™) combined with the cancer killing prodrug ifosfamide—can also delay the rate of production and accumulation of malignant ascites.
Lead Product(s):
Encapsulated Live Cells Converting Ifosamide
Analysis after 18 months in storage at -80oC, the unfrozen CypCaps product passed all the specified tests, including cell viability, enzyme activity, cell potency, pH, label check, capsule appearance and integrity.
Market Place
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
